Role of immune mediators in predicting hospitalization of SARS-CoV-2 positive patients. (February 2022)

• Record Type: Journal Article
• Authors: Ashrafzadeh-Kian, S.; Campbell, M.R.; Jara Aguirre, J.C.; Walsh, J.; Kumanovics, A.; Jenkinson, G.; Rinaldo, P.; Snyder, M.R.; Algeciras-Schimnich, A.
• Is Part Of: Cytokine. Volume 150(2022)
• Publication Date: 2022-02
• Subjects: COVID-19 -- SARS-CoV-2 -- IL-6 -- Immune mediator -- Multiplex assay -- Hospitalization; IM Immune Mediator -- LLOQ Lower Limit of Quantification -- AMR Analytic Measuring Range -- SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 -- COVID-19 Coronavirus disease 2019 -- GM-CSF Granulocyte-macrophage colony-stimulating factor -- IFNα IFNβ, IFNγ, Interferon α, β, γ -- IL Interleukin -- IL-1β Interleukin 1 beta -- sIL-2Rα Interleukin 2 receptor α (soluble) -- IL-6 Interleukin 6 -- sIL-6Rα Interleukin 6 receptor α (soluble) -- IL-10 Interleukin 10 -- IL-18 Interleukin 18 -- MCP-1 Monocyte chemoattractant protein-1 -- MIP-1α Macrophage inflammatory protein 1α -- TNF TNF-α, Tumor necrosis factor-alpha -- VEGF Vascular endothelial growth factor -- IP-10 CXCL-10, Interferon gamma-induced protein 10 -- vWF-A2 von Willebrand factor A2 domain -- FGF Fibroblast growth factor -- G-CSF Granulocyte colony-stimulating factor -- PDGF Platelet-derived growth factor -- EN-RAGE/S100A12 Extracellular newly identified receptor for advanced glycation end products binding protein -- LIF Leukemia inhibitory factor -- CLIR Collaborative Laboratory Integrated Reports; Cytokines -- Periodicals; 571.844
• DOI: 10.1016/j.cyto.2021.155790
• Languages: English
• ISSNs: 1043-4666

Abstract

Highlights: IL-6 is a predictive marker of the need for hospitalization and severity in COVID-19. Immune mediator profiles in hospitalized and non-hospitalized patients are distinct. Correlations between immune mediators differ between hospitalized and non-hospitalized groups. Abstract: Background: Several immune mediators (IM) including cytokines, chemokines, and their receptors have been suggested to play a role in COVID-19 pathophysiology and severity. Aim: To determine if early IM profiles are predictive of clinical outcome and which of the IMs tested possess the most clinical utility. Methods: A custom bead-based multiplex assay was used to measure IM concentrations in a cohort of SARS-CoV-2 PCR positive patients (n = 326) with varying disease severities as determined by hospitalization status, length of hospital stay, and survival. Patient groups were compared, and clinical utility was assessed. Correlation plots were constructed to determine if significant relationships exist between the IMs in the setting of COVID-19. Results: In PCR positive SARS-CoV-2 patients, IL-6 was the best predictor of the need for hospitalization and length of stay. Additionally, MCP-1 and sIL-2Rα were moderate predictors of the need for hospitalization. Hospitalized PCR positive SARS-CoV-2 patients displayed a notable correlation between sIL-2Rα and IL-18 (Spearman's ρ = 0.48, P=<0.0001). Conclusions: IM profiles between non-hospitalized and hospitalized patients were distinct. IL-6 was the best predictor of COVID-19 severity among all the IMs tested.